- Policy
- MOHW ‘is discussing expanding non-face-to-face treatment’
- by Lee, Jeong-Hwan Sep 1, 2023 05:44am
- The Ministry of Health and Welfare formalized the expansion of the scope of its non-face-to-face medical treatment pilot project, and announced plans to expand the scope of first-time examinations, ease the standards for re-examination, and increase the ‘within 30 days of initial treatment’ term allowed for reexamination of acute condition
- Policy
- The 1st results of the pharmaceutical benefit re-evaluation
- by Lee, Tak-Sun Sep 1, 2023 05:43am
- The HIRA does not plan to disclose the first results of the benefit re-evaluation reviewed by the committee on this day. After notifying the pharmaceutical company of the results, we plan to receive objections and then disclose the results during the second review. According to HIRA and the pharmaceutical industry on the 31st, the results of
- Policy
- Cold medicine bills increased by 90% due to the coronavirus
- by Lee, Tak-Sun Aug 31, 2023 05:25am
- Due to the increase in confirmed cases of COVID-19 last year, cold medicine bills alone increased by 90% compared to the previous year. Based on the past five years, claims for COVID-19-related drugs were the highest in 2022. The NHIS conducted negotiations on linking usage and drug price reduction for 36 items related to COVID-19 and agreed
- Policy
- NHIS may cover high-priced new drugs with refund-type RSA
- by Lee, Tak-Sun Aug 31, 2023 05:25am
- The National Health Insurance Service is planning to improve the Risk Sharing Agreement (RSA) Scheme and is also discussing measures to improve the Price-Volume Agreement (PVA) system to reflect rewards for the innovative value of new drugs. The Department of Drug Management at NHIS said so at a press conference with correspondents on the
- Policy
- Opdivo reimb as first-line therapy in gastric cancer in KOR
- by Lee, Tak-Sun Aug 29, 2023 05:28am
- The immuno-oncology drug Opdivo will be available for use as a first-line treatment, and the administration subjects for Imbruvica and G-CSF injections will be expanded. The Health Insurance Review and Assessment Service started collecting opinions on the amendment of the reimbursement standards that contain the changes above from the 24th.
- Policy
- Hyundai Pharm's Hypejil 3mg
- by Lee, Tak-Sun Aug 29, 2023 05:28am
- A 3mg low-dose product is listed for the first time in a Donepezil tablet used to treat Alzheimer's. The main character is Hyundai Pharm's 'Hypejil Tablet 3mg'. This drug will be paid from September to 486 won for the party according to the calculation criteria. According to the industry on the 25th, 3 mg of Donepezil is the first time
- Policy
- MOHW-Roche have difficulty discussing resupply of Madopar
- by Lee, Jeong-Hwan Aug 28, 2023 05:21am
- The Ministry of Health and Welfare seems to be having difficulty bringing in Madopar, a Parkinson's disease drug that had withdrawn from the domestic market, back to Korea. The MOHW had previously announced that it would make efforts to resupply Madopar in Korea. Roche Korea is known to have refused to supply Madopar Tab to Korea, citing
- Policy
- Are there any countermeasures against Rx of hair loss pills?
- by Lee, Jeong-Hwan Aug 25, 2023 06:06am
- The Health and Welfare Committee of the National Assembly will start reviewing legislation to institutionalize non-face-to-face treatment, excluding the prescription restriction bill for high-risk non-insured drugs such as hair loss treatment, which is being prepared by Rep. Jeon Hye-sook, and the public e-prescription legislation proposed by
- Policy
- Bayer completes pricing negotiations for Jivi Inj in KOR
- by Lee, Tak-Sun Aug 25, 2023 06:06am
- Bayer’s s hemophilia A treatment ‘Jivi Inj (damoctocog alfa pegol)’ has come one step near to receiving reimbursement in Korea. On the other hand, reimbursement discussions for Lilly Korea’s ‘Retevmo (selpercatinib)’ have returned to square one after the company failed to complete pricing negotiations for its RET targeted anticance
- Policy
- Reduction in the scope of platform regulation & re-examinati
- by Lee, Jeong-Hwan Aug 25, 2023 06:06am
- Following the decision to postpone the non-face-to-face treatment institutionalization bill again by the National Assembly Health and Welfare Committee on the 24th, it is evaluated that the number of issues to be resolved for legislation has increased. At the same time, the need to reduce the scope of non-face-to-face treatment patients comp
